Intercept Pharmaceuticals
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
10/10
|
3.48 | 57.09 | -93.91% | -2.15 | -261.34% |
| P/S |
|
1.4 | 33.5 | -95.82% |
|
|
| P/BV |
|
4.3 | 4.61 | -6.79% |
|
|
| P/FCF |
|
-15.99 | 39.66 | -140.32% |
|
|
| Ev/Ebitda |
|
-11.06 | -19.46 | -43.14% |
|
|
| Ev/S |
|
2.39 | 22.56 | -89.41% |
|
|
| Ev/FCF |
|
-25 | 45.47 | -154.97% |
|
|
| E/P |
|
0.2639 | 0.0172 | 1430.09% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
-21.6 | -14.42 | 49.76% | -30.68 | -29.6% |
| ROE |
|
-253.45 | 9.01 | -2912.86% |
|
|
| ROA |
|
21.31 | 0.0151 | 140635.58% |
|
|
| ROIC |
|
0 | 7.63 | -100% |
|
|
| ROS |
|
40.32 | -26.5 | -252.12% |
|
|
| ROCE |
|
-73.25 | 13.75 | -632.61% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-5.39 | -3.73 | 44.62% | -4.79 | +12.61% |
| Nеt Debt/Ebitda |
|
-4.57 | -3.19 | 43.23% |
|
|
| Debt/Ratio |
|
0.6009 | 0.1777 | 238.1% |
|
|
| Debt/Equity |
|
44.96 | 1.57 | 2760.84% |
|
|
| Debt/Net Income |
|
2.89 | 0.8429 | 242.62% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.5467 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.7368 | -100% | ||
| DSI |
|
0 | 0.2387 | -100% |
|
|
| Average dividend growth |
|
0 | 1.55 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 0.4967 | -100% |
|
|
| Average percentage for payments |
|
0 | 43.73 | -100% |
|
|
| Difference from average difference in sector |
|
-0.5467 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
3/10
|
16.87 | 73.67 | -77.1% | ||
| Growth impulse Ebitda in 5 years |
|
-78.03 | 15.28 | -610.67% | ||
| Growth impulse Net Income in 5 years |
|
-131.61 | -33.08 | 297.85% | ||
| Growth impulse FCF in 5 years |
|
-75.29 | -6.99 | 977.11% | ||
| Growth impulse EPS in 5 years |
|
-124.03 | -59.11 | 109.83% |
IP Score
3.45/10
